Technical Analysis for TCRR - TCR2 Therapeutics Inc.

Grade Last Price % Change Price Change
F 26.64 0.00% 0.00
TCRR closed down 6.3 percent on Tuesday, March 2, 2021, on 62 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical TCRR trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.30%
Crossed Above 20 DMA Bullish -6.30%
Pocket Pivot Bullish Swing Setup -6.30%
Bollinger Band Squeeze Range Contraction -6.30%
20 DMA Resistance Bearish 0.68%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.68%
Bollinger Band Squeeze Range Contraction 0.68%
Outside Day Range Expansion 0.68%
Older End-of-Day Signals for TCRR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Lower Bollinger Band about 22 hours ago
Down 1 ATR about 23 hours ago
60 Minute Opening Range Breakdown about 23 hours ago
Down 5% about 23 hours ago
Down 3% about 23 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


TCR2 Therapeutics Inc. Description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Lymphoma Cancer Immunotherapy Small Cell Lung Cancer Ovarian Cancer Non Small Cell Lung Cancer Carcinoma Proteins Acute Lymphoblastic Leukemia Helio Hematological Malignancies Treatment Of Non Small Cell Lung Cancer Cd19 Nsclc Tumors Of The Hematopoietic And Lymphoid Tissues Immunogen Mesothelioma Mesothelin Cholangiocarcinoma Diffuse Large B Cell Lymphoma Positive Solid Tumors

Is TCRR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 35.86
52 Week Low 5.84
Average Volume 500,068
200-Day Moving Average 21.62
50-Day Moving Average 29.13
20-Day Moving Average 27.82
10-Day Moving Average 27.65
Average True Range 1.81
ADX 15.63
+DI 15.70
-DI 24.14
Chandelier Exit (Long, 3 ATRs ) 24.66
Chandelier Exit (Short, 3 ATRs ) 30.85
Upper Bollinger Band 29.68
Lower Bollinger Band 25.96
Percent B (%b) 0.18
BandWidth 13.37
MACD Line -0.46
MACD Signal Line -0.42
MACD Histogram -0.0435
Fundamentals Value
Market Cap 890.36 Million
Num Shares 33.4 Million
EPS -10.67
Price-to-Earnings (P/E) Ratio -2.50
Price-to-Sales 0.00
Price-to-Book 3.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.55
Resistance 3 (R3) 29.73 28.93 29.07
Resistance 2 (R2) 28.93 28.19 28.85 28.90
Resistance 1 (R1) 27.79 27.73 27.39 27.61 28.74
Pivot Point 26.99 26.99 26.80 26.91 26.99
Support 1 (S1) 25.85 26.25 25.45 25.67 24.54
Support 2 (S2) 25.05 25.79 24.97 24.38
Support 3 (S3) 23.91 25.05 24.22
Support 4 (S4) 23.73